Drug Search Results
More Filters [+]

4D-310

Alternative Names: 4D-310, 4D310
Latest Update: 2024-04-08
Latest Update Note: Clinical Trial Update

Product Description

4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04519749)

Mechanisms of Action: Gene Therapy,GLA

Novel Mechanism: No

Modality: Gene Therapy

Route of Administration: Intravenous

FDA Designation: Fast Track - Fabry Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: 4D Molecular
Company Location: EMERYVILLE CA 94608
Company CEO: David Kirn
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 4D-310

Countries in Clinic: Australia, Taiwan, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Fabry Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

4D-310-C001

P2

Active, not recruiting

Fabry Disease

2026-01-01

32%

4D-310-C002

P2

Active, not recruiting

Fabry Disease

2026-01-01

32%

Recent News Events